secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0000950170-25-089942
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva stockholders approve 1.2M share increase to 2024 equity plan, re-elect director Baker
--------------------------------------------------------------------------------

- Amendment to 2024 Equity Incentive Plan approved, adding 1,214,580 shares to the share reserve; total now up to 7,001,185 shares.
- Class I director Daniel Baker, Ph.D., re-elected with 18.9M votes for (98.9% of votes cast), 22,995 withheld.
- KPMG LLP ratified as independent auditor for FY2025 with 20.8M votes for, 300 against, 2,272 abstain.
- Plan also provides annual automatic increase of up to 5% of outstanding shares each January 1 through 2034.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025089942/0000950170-25-089942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025089942/artv-20250624.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-089942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer